CFO Matthew Korenberg said, “Palvella ended Q1 with $261.9 million in cash and cash equivalents,” and tied runway confidence to the “oversubscribed $230 million equity offering,” adding the company ...
Welcome to Wiley’s update on recent developments and what’s next in consumer protection enforcement and regulation. We cover developments with ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results